Print Page   |   Contact Us   |   Sign In
Community Search
 ADVERTISEMENTS 
This section will be used for adverts.
Pharmaceutical Companies can advertise here.
Adverts will be rated and run on monthly basis.
it will be first come first served basis


BNF:
Available at the PSGH secretariat
  • British National Formulary 
    Book by Royal Pharmaceutical Society of Great Britain and British Medical Association
  • The British National Formulary is a pharmaceutical reference book that contains a wide spectrum of information and advice on prescribing and pharmacology, along with specific facts and details about medicines.
  • PSGH CLOTH and other materials
  • Available at the PSGH Secretariat

  • News & Press: FDA

    Ban on Codeine-containing Cough Syrups

    Tuesday, 27 November 2018   (0 Comments)
    Posted by: Paul Owusu Donkor
    Share |

    Ban on Codeine-containing Cough Syrups

     

    All registration and market authorisation covering codeine-containing cough syrups, Diphex® with codeine cough syrup, Benylin® with codeine cough syrup and Actifed® dry cough and cold syrup have been revoked. This directive was issued by the Minister for Health, acting through Executive Instrument E. I. 167. The Executive Instrument was gazetted on 26th September, 2018.

    The ban on codeine-containing cough syrups follows after the technical report submitted by the Food and Drugs Authority (FDA) to the Ministry of Health.

    ________________________________________________________________________

    Related Links:

    Restricted Use of Tramadol and Tramadol-containing Products

    ________________________________________________________________________ 

    Currently, all other approved dosage forms and strengths of codeine registered by the FDA for other indications in adults and children shall be re-classified as “Controlled Drugs” and dispensed only upon proof of a valid prescription and a record of prescriptions kept. Furthermore, all other approved dosage forms and strengths of codeine registered by the FDA for distribution, dispensing and use shall be re-classified as “Prescription Only Medicines” and maintained as such.